Akèy › Kansè ovè › Illinois › Chicago
Etid klinik pou Kansè ovè nan Chicago, IL
36 etid pou Kansè ovè ap chèche patisipan nan sit nan ak bò kote Chicago (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- Research Site, Chicago
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Ap rekriteFaz 2/3
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- Northwestern Medicine Cancer Center Old Irving Park, Chicago
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Ap rekriteFaz 2
- Mount Sinai Hospital Medical Center, Chicago
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- ak 3 plis
A Study of PHST001 in Advanced Solid Tumors
Ap rekriteFaz 1
- University of Chicago Medical Center, Chicago
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- University of Chicago Hospital, Chicago
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- University of Illinois Cancer Center, Chicago
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
Ap rekriteFaz 1
- University of Chicago Medical Center /ID# 278295, Chicago
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Ap rekriteEtid obsèvasyon
- University of Chicago, Chicago
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Ap rekriteFaz 2
- Rush Md Anderson Cancer Center /ID# 274926, Chicago
- University of Chicago Medical Center /ID# 274796, Chicago
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Ap rekriteFaz 1/2
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
- University of Chicago Medical Center, Chicago
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ap rekriteFaz 3
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- The University of Chicago Medicine, Chicago
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Ap rekriteFaz 1
- Northwestern University Feinberg School of Medicine, Chicago
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ap rekriteFaz 3
- The University of Chicago Medicine, Chicago
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ap rekriteFaz 2
- University of Chicago, Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
Ap rekriteFaz 2
- University of Chicago, Chicago
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Ap rekriteFaz 1
- University of Chicago Medical Center, Chicago
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ap rekriteFaz 1/2
- Lurie Children's Hospital-Chicago, Chicago
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ap rekrite
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
- ak 2 plis
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Ap rekriteFaz 3
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- ak 1 plis
A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine
Ap rekriteFaz 1
- Rush University Medical Center, Chicago
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Ap rekriteFaz 2
- The University of Chicago Medical Center, Chicago
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
Ap rekriteFaz 2
- Northwestern Memorial Hospital, Chicago
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Ap rekriteFaz 1
- UChicago Medicine - River East, Chicago
- The University Of Chicago, Chicago
- University of Chicago Medical Center, Chicago
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Ap rekriteFaz 1/2
- Northwestern University, Chicago
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Ap rekriteFaz 1/2
- Northwestern Memorial Hospital, Chicago
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
Ap rekrite
- Northwestern University, Chicago
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Ap rekriteFaz 1/2
- University of Chicago Medical Center, Chicago
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Ap rekrite
- UChicago Medicine, Chicago
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- University of Chicago Medical Center, Chicago
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
Ap rekrite
- Northwestern Memorial Hospital, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- The University of Chicago Comprehensive Cancer Center, Chicago
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Ap rekriteFaz 2
- University of Chicago Medical Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Chicago
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Ap rekriteFaz 2
- Northwestern University, Chicago
Etid Kansè ovè nan lòt vil
- Houston, TX89 etid
- New York City, NY69 etid
- Boston, MA61 etid
- Los Angeles, CA50 etid
- Nashville, TN49 etid
- Arlington, VA46 etid
- Philadelphia, PA44 etid
- Columbus, OH39 etid
- St. Louis, MO38 etid
- San Antonio, TX31 etid
- Cleveland, OH30 etid
- Pittsburgh, PA30 etid
Lòt etid nan Chicago
- Kansè Poumon ki pa ti selil61 etid
- Kansè nan tete59 etid
- Kansè (tout kalite)51 etid
- Kansè Metastatik45 etid
- Kansè pwostat45 etid
- Kansè poumon41 etid
- Obèsite41 etid
- Kansè kolorektal34 etid
- Akidan serebavaskilè34 etid
- Ensifizyans kadyak31 etid
- Sipwa29 etid
- Karsinòm selil skuamèz tèt ak kou26 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.